# Project Context
The BITCORE Antibody Research System is a project focused on antibody research and development, aiming to achieve full domination in the 2025 AbDev Competition by demonstrating superior capacity in antibody developability prediction. The system involves executing research swarms for antibody developability and analyzing one antibody developability parameter at a time.

# Keywords
antibody developability, computational prediction, machine learning, antibody design, biophysical properties, polyreactivity, aggregation, therapeutic antibodies, AI in drug discovery, antibody optimization

# Recommended Citations
1. Zippelius, A., et al. (2025). Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment. Nature Reviews Cancer. https://doi.org/10.1038/s41568-025-00869-w
2. Crescioli, S., et al. (2025). Antibodies to watch in 2025. MAbs, 17, 2443538. https://doi.org/10.1080/19420862.2025.2443538
3. Marshall, A., & Nordling, L. (2025). Merck’s anti-RSV antibody expands protection for infants. Nature Biotechnology, 43, 837–840. https://doi.org/10.1038/s41587-025-02713-w
4. Chen, Z., Feng, L., & Wang, L. (2025). A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Signal Transduction and Targeted Therapy, 10, 14. https://doi.org/10.1038/s41392-024-02114-6
5. Dolan, B., Correa Gaviria, T., & Dong, Y. (2025). mosGILT antibodies interfere with Plasmodium sporogony in Anopheles gambiae. Nature Communications, 16, 592. https://doi.org/10.1038/s41467-025-55902-1
6. He, Y., Yin, Y., & Zhang, Y. (2025). Dynamics of neutralizing antibodies against COVID-19 Omicron subvariants following breakthrough infection in southwest China between December 2022 and April 2024. Signal Transduction and Targeted Therapy, 10, 242. https://doi.org/10.1038/s41392-025-02319-3
7. Garber, K. (2025). First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-025-00029-7

# Relevance Summary

1. The ADC molecular drivers citation provides critical insights into the immunological mechanisms of antibody-drug conjugates, which can inform our AI models on optimizing antibody payloads and linker technologies for enhanced therapeutic efficacy.

2. The "Antibodies to watch" citation offers a comprehensive overview of recently approved and registrational-stage antibody therapeutics, serving as a valuable benchmark for our developability prediction models and target selection strategies.

3. The Merck anti-RSV antibody citation details clinical advancements in long-lasting antibody protection for infants, providing real-world data on antibody pharmacokinetics and safety profiles that can train our prediction algorithms.

4. The broadly neutralizing antibody against Omicron sub-variants citation presents structural and functional analysis of antibodies with exceptional breadth, offering templates for designing next-generation antibodies with enhanced variant resistance.

5. The mosGILT antibody study demonstrates innovative applications of antibodies in malaria prevention, expanding our understanding of antibody functionality beyond traditional therapeutic contexts and inspiring novel design approaches.

6. The Omicron subvariant neutralizing antibody dynamics citation provides longitudinal data on antibody responses following breakthrough infections, offering valuable insights into immune evasion mechanisms that can improve our developability assessments.

7. The myostatin blocker citation covers the first muscle-growing antibody nearing FDA approval, representing a breakthrough in targeting previously undruggable pathways and providing case study data for our competition entry.